{"id":"https://openalex.org/W4200108652","doi":"https://doi.org/10.1093/ofid/ofab466.1579","title":"1387. Impact of Cytomegalovirus Prophylaxis on Healthcare Resource Use and Costs among Kidney Transplant Recipients: A United States Renal Data System-Medicare Linked Database Study","display_name":"1387. Impact of Cytomegalovirus Prophylaxis on Healthcare Resource Use and Costs among Kidney Transplant Recipients: A United States Renal Data System-Medicare Linked Database Study","publication_year":2021,"publication_date":"2021-11-01","ids":{"openalex":"https://openalex.org/W4200108652","doi":"https://doi.org/10.1093/ofid/ofab466.1579"},"language":"en","primary_location":{"id":"doi:10.1093/ofid/ofab466.1579","doi":"https://doi.org/10.1093/ofid/ofab466.1579","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofab466.1579","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1093/ofid/ofab466.1579","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081547217","display_name":"Amit D. Raval","orcid":"https://orcid.org/0000-0001-8265-8612","observed_orcids":["https://orcid.org/0000-0001-8265-8612"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amit D Raval","raw_affiliation_strings":["Merck and Co., Inc., Rahway, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck and Co., Inc., Rahway, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047100651","display_name":"Michael Lee Ganz","orcid":"https://orcid.org/0000-0002-9702-2999","observed_orcids":["https://orcid.org/0000-0002-9702-2999"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Ganz","raw_affiliation_strings":["Evidera, Inc., Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidera, Inc., Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024759328","display_name":"Priya Saravanan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Priya Saravanan","raw_affiliation_strings":["Evidera, Inc., Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidera, Inc., Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010827456","display_name":"Yuexin Tang","orcid":"https://orcid.org/0000-0001-6528-4145","observed_orcids":["https://orcid.org/0000-0001-6528-4145"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuexin Tang","raw_affiliation_strings":["Merck and Co., Inc, North wales, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck and Co., Inc, North wales, Pennsylvania","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102980347","display_name":"Carlos A.Q. Santos","orcid":"https://orcid.org/0000-0002-6224-0371","observed_orcids":["https://orcid.org/0000-0002-6224-0371"]},"institutions":[{"id":"https://openalex.org/I1285301757","display_name":"Rush University Medical Center","ror":"https://ror.org/01j7c0b24","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285301757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carlos Santos","raw_affiliation_strings":["Rush University Medical Center, Chicago, Illinois"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rush University Medical Center, Chicago, Illinois","institution_ids":["https://openalex.org/I1285301757"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3465,"currency":"USD","value_usd":3465},"apc_paid":{"value":3465,"currency":"USD","value_usd":3465},"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"8","issue":"Supplement_1","first_page":"S779","last_page":"S779"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10981","display_name":"Cytomegalovirus and herpesvirus research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10981","display_name":"Cytomegalovirus and herpesvirus research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10373","display_name":"Renal Transplantation Outcomes and Treatments","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2747","display_name":"Transplantation"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cmv-prophylaxis","display_name":"CMV prophylaxis","score":0.9819999933242798},{"id":"https://openalex.org/keywords/kidney-transplant-recipients","display_name":"kidney transplant recipients","score":0.8870000243186951},{"id":"https://openalex.org/keywords/health-care-utilization","display_name":"health care utilization","score":0.8259999752044678},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.9660000205039978},{"id":"https://openalex.org/keywords/valganciclovir","display_name":"valganciclovir","score":0.8970000147819519},{"id":"https://openalex.org/keywords/valacyclovir","display_name":"valacyclovir","score":0.9869999885559082},{"id":"https://openalex.org/keywords/hospitalization-costs","display_name":"hospital costs","score":0.746999979019165},{"id":"https://openalex.org/keywords/hospital-readmission","display_name":"hospital readmission","score":0.9599999785423279},{"id":"https://openalex.org/keywords/opportunistic-infections","display_name":"opportunistic infections","score":0.9580000042915344},{"id":"https://openalex.org/keywords/antiviral-toxicity","display_name":"antiviral toxicity","score":0.6499999761581421},{"id":"https://openalex.org/keywords/medicare-spending","display_name":"Medicare spending","score":0.3880000114440918},{"id":"https://openalex.org/keywords/united-states-renal-data-system","display_name":"United States Renal Data System","score":0.746999979019165},{"id":"https://openalex.org/keywords/medicare-part-d","display_name":"Medicare Part D","score":0.47999998927116394},{"id":"https://openalex.org/keywords/post-transplant-care","display_name":"post-transplant care","score":0.49399998784065247}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9508780241012573},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.5929840207099915},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.46947726607322693},{"id":"https://openalex.org/C2776317777","wikidata":"https://www.wikidata.org/wiki/Q423384","display_name":"Valganciclovir","level":5,"score":0.4605063796043396},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4437275528907776},{"id":"https://openalex.org/C2777732132","wikidata":"https://www.wikidata.org/wiki/Q6946","display_name":"Cytomegalovirus","level":5,"score":0.440502405166626},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.43198150396347046},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4018611013889313},{"id":"https://openalex.org/C77088390","wikidata":"https://www.wikidata.org/wiki/Q8513","display_name":"Database","level":1,"score":0.381588339805603},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.3632391691207886},{"id":"https://openalex.org/C2777965375","wikidata":"https://www.wikidata.org/wiki/Q417640","display_name":"Ganciclovir","level":4,"score":0.2550659775733948},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.17424362897872925},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.15765133500099182},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.15383124351501465},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.13804897665977478},{"id":"https://openalex.org/C2779820661","wikidata":"https://www.wikidata.org/wiki/Q6929","display_name":"Human cytomegalovirus","level":3,"score":0.07903391122817993},{"id":"https://openalex.org/C2776409557","wikidata":"https://www.wikidata.org/wiki/Q149348","display_name":"Herpesviridae","level":4,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1093/ofid/ofab466.1579","doi":"https://doi.org/10.1093/ofid/ofab466.1579","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofab466.1579","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8644577","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8644577","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infect Dis","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/ofid/ofab466.1579","doi":"https://doi.org/10.1093/ofid/ofab466.1579","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofab466.1579","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4200177497","https://openalex.org/W2084832002","https://openalex.org/W2008640624","https://openalex.org/W1986365927","https://openalex.org/W4309030478","https://openalex.org/W1995066186","https://openalex.org/W3097371521","https://openalex.org/W2308897354","https://openalex.org/W2293543841","https://openalex.org/W4250788529"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Cytomegalovirus":[2],"(CMV)":[3],"management":[4],"requires":[5],"a":[6,71,209,219,290,297],"balance":[7],"between":[8],"reducing":[9],"the":[10,24,30,44,59,81],"risk":[11,61],"of":[12,26,73,146,156,160,178,190,247,281,293],"CMV":[13,27,55,60,119,137,205,241,287],"infection":[14,253],"and":[15,35,51,107,112,144,149,163,176,193,198,250,271,304,311,316,325],"avoiding":[16],"anti-viral":[17],"toxicities.":[18],"Limited":[19],"information":[20],"is":[21],"available":[22],"on":[23,29],"impact":[25],"prophylaxis":[28,56,120,130,138,157,168,206,242,259,288],"healthcare":[31,223],"resource":[32],"use":[33],"(HCRU)":[34],"costs":[36],"among":[37,63,195],"adult":[38],"kidney":[39],"transplant":[40],"recipients":[41],"(KTRs)":[42],"in":[43,97,141,173,314],"United":[45],"States.":[46],"Therefore,":[47],"we":[48],"examined":[49],"HCRU":[50],"cost":[52,155,189,214,225,235,280,292,300],"associated":[53],"with":[54,152,186,277,301],"stratified":[57],"by":[58],"categories":[62],"KTRs":[64,77,151,159,179],"at":[65],"1-year":[66],"post-KT.":[67,118,135],"Methods":[68],"We":[69],"identified":[70],"cohort":[72],"22,918":[74],"adults":[75],"first-time":[76],"during":[78],"2011\u20132017":[79],"using":[80],"US":[82],"Renal":[83],"Data":[84],"System":[85],"registry-linked":[86],"Medicare":[87,98,113],"data.":[88],"Additional":[89],"inclusion":[90],"criteria":[91],"were":[92,309],"to":[93,231,257],"have":[94],"continuous":[95],"coverage":[96],"Part":[99,114],"A":[100],"&":[101,340],"B":[102],"for":[103,116,128],"\u2265":[104,108,124],"6-month":[105],"pre-":[106],"12-month":[109],"post":[110],"KT":[111],"D":[115],"\u226512-month":[117],"was":[121,139,171],"confirmed":[122],"as":[123],"1":[125],"prescription":[126,212],"fill":[127],"valacyclovir/(val)ganciclovir":[129],"doses":[131],"within":[132],"28":[133],"days":[134],"Results":[136],"utilized":[140,172],"86%,":[142],"82%,":[143],"32%":[145,266],"high,":[147,196],"intermediate,":[148,197],"low-risk":[150,199],"an":[153,187,278],"average":[154,188,221,279],"per":[158,283],"&16,241,":[161],"&9481,":[162],"&8,648,":[164],"respectively.":[165,201],"In":[166,262],"no":[167,258],"groups,":[169],"valganciclovir":[170],"52%,":[174],"34%,":[175],"36%":[177],"(as":[180],"either":[181],"pre-emptive":[182],"or":[183,335],"deferred":[184],"therapy)":[185],"&6,719,":[191],"&2,722,":[192],"&431":[194],"KTRs,":[200,204,264],"Among":[202],"high-risk":[203,263],"group":[207,243],"had":[208,244,267,289,296],"significantly":[210],"higher":[211,291],"drug":[213],"(&26,060":[215],"vs.":[216,227,237],"&13,433)":[217],"but":[218,295],"lower":[220,232,245,298],"direct":[222],"medical":[224,299],"(&84,914":[226],"&101,268),":[228],"mainly":[229],"due":[230],"all-cause":[233,248,303],"hospitalization":[234,255],"(&56,758":[236],"&69,852)":[238],"(Table":[239,260],"1).":[240],"rates":[246],"rehospitalization,":[249],"CMV-and":[251],"opportunistic":[252],"(OIs)-related":[254],"compared":[256],"2).":[261],"nearly":[265],"myelosuppressive":[268],"events-related":[269],"hospitalization,":[270],"15%":[272],"filled":[273],"granulocyte":[274],"colony-stimulating":[275],"factors":[276],"&4,695":[282],"treated":[284],"KTR.":[285],"Conclusion":[286],"medications":[294],"including":[302],"CMV-related":[305],"hospitalizations.":[306],"Myelosuppressive":[307],"events":[308],"frequent":[310],"resource-intensive":[312],"especially":[313],"high":[315],"intermediate-risk":[317],"KTRs.":[318],"Disclosures":[319],"Amit":[320],"D.":[321],"Raval,":[322],"PhD,":[323,331],"Merck":[324],"Co.,":[326,341],"Inc.":[327,342],"(Employee)":[328],"Yuexin":[329],"Tang,":[330],"JnJ":[332],"(Other":[333],"Financial":[334],"Material":[336],"Support,":[337],"Spouse\u2019s":[338],"employment)Merck":[339],"(Employee,":[343],"Shareholder)":[344]},"counts_by_year":[{"year":2025,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2021-12-31T00:00:00"}